← Back to Search

Virus Therapy

AdCOVID for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Altimmune, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 to day 366
Awards & highlights

Study Summary

This study is evaluating whether a nasal spray may help treat the common cold.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 to day 366
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 to day 366 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events (AEs)
Reactogenicity
Secondary outcome measures
Anti-SARS-CoV-2 spike IgG antibody levels
Neutralizing antibody titer against live and/or pseudotyped SARS-CoV-2 virus
Other outcome measures
Anti-SARS-CoV-2 RBD T cell responses by interferon (IFN)-gamma enzyme-linked immunosorbent spot (ELISpot)
Mucosal antibody responses in nasopharyngeal swabs (anti-SARS-CoV-2 spike IgA titers)

Trial Design

8Treatment groups
Experimental Treatment
Placebo Group
Group I: Two Medium Doses AdCOVIDExperimental Treatment1 Intervention
Group II: Two Low Doses AdCOVIDExperimental Treatment1 Intervention
Group III: Two High Doses AdCOVIDExperimental Treatment1 Intervention
Group IV: Single Medium Dose AdCOVIDExperimental Treatment1 Intervention
Group V: Single Low Dose AdCOVIDExperimental Treatment1 Intervention
Group VI: Single High Dose AdCOVIDExperimental Treatment1 Intervention
Group VII: Two Dose PlaceboPlacebo Group1 Intervention
Group VIII: Single Dose PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AdCOVID
2021
Completed Phase 1
~100

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Altimmune, Inc.Lead Sponsor
16 Previous Clinical Trials
1,446 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)
2021. "Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04679909.
~23 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top